Clear Harbor Asset Management LLC Has $261,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

Clear Harbor Asset Management LLC boosted its stake in Arbutus Biopharma Co. (NASDAQ:ABUS) by 6.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 79,761 shares of the biopharmaceutical company’s stock after purchasing an additional 5,000 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Arbutus Biopharma were worth $261,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABUS. Ballentine Partners LLC bought a new stake in shares of Arbutus Biopharma during the fourth quarter valued at approximately $102,000. JPMorgan Chase & Co. increased its stake in Arbutus Biopharma by 11.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 89,586 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 8,859 shares in the last quarter. Barclays PLC raised its holdings in Arbutus Biopharma by 466.3% during the third quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company’s stock worth $1,047,000 after buying an additional 223,995 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Arbutus Biopharma by 4.1% in the third quarter. Geode Capital Management LLC now owns 3,448,600 shares of the biopharmaceutical company’s stock valued at $13,280,000 after buying an additional 135,442 shares in the last quarter. Finally, XTX Topco Ltd lifted its stake in shares of Arbutus Biopharma by 76.2% in the third quarter. XTX Topco Ltd now owns 30,013 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 12,975 shares in the last quarter. 43.79% of the stock is owned by institutional investors.

Analyst Ratings Changes

ABUS has been the topic of a number of analyst reports. Chardan Capital restated a “buy” rating and issued a $5.00 target price (up previously from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research note on Tuesday. Finally, JMP Securities lifted their target price on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Arbutus Biopharma currently has an average rating of “Moderate Buy” and an average target price of $5.50.

Arbutus Biopharma Stock Up 0.3 %

Arbutus Biopharma stock opened at $3.22 on Thursday. Arbutus Biopharma Co. has a 52 week low of $2.27 and a 52 week high of $4.72. The company’s 50 day moving average price is $3.40 and its two-hundred day moving average price is $3.72. The stock has a market cap of $610.16 million, a P/E ratio of -7.49 and a beta of 1.78.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.